SCHEMBL1361994

SCHEMBL1361994

C=CCOC(=O)C12CC3SC(C1)SC(C2)S3

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.33
EPHX2 P34913 1/20 0.33
ALDH1A1 P00352 6/20 0.33
TSHR P16473 2/20 0.33
HSD17B10 Q99714 2/20 0.33
MAPT P10636 4/20 0.32
MEN1 O00255 3/20 0.32
KMT2A Q03164 3/20 0.32
NPSR1 Q6W5P4 1/20 0.32
CACNA1B Q00975 1/20 0.32
APBA1 Q02410 1/20 0.32
GAA P10253 2/20 0.31
PRKCA P17252 1/20 0.31
KDM4E B2RXH2 2/20 0.31
LMNA P02545 1/20 0.31
MAPK1 P28482 1/20 0.31
TDP1 Q9NUW8 1/20 0.30
CA1 P00915 1/20 0.30
CA2 P00918 1/20 0.30
TP53 P04637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7797331 0.80 ALDH1A1 (0.50) CYP3A4EPHX2ALDH1A1MAPTMEN1
SCHEMBL6559200 0.77 CYP3A4 (0.39) CYP3A4EPHX2ALDH1A1TSHRHSD17B10
SCHEMBL6560524 0.76 NPSR1 (0.41) CYP3A4EPHX2ALDH1A1TSHRMAPT
SCHEMBL1359743 0.76 LMNA (0.38) ALDH1A1HSD17B10MAPTMEN1KMT2A
SCHEMBL6559153 0.74 NPSR1 (0.53) EPHX2ALDH1A1MAPTMEN1KMT2A
SCHEMBL1733422 0.70 CYP3A4 (0.35) CYP3A4ALDH1A1TSHRHSD17B10MAPT
SCHEMBL9638887 0.70 TSHR (0.37) CYP3A4EPHX2ALDH1A1TSHRHSD17B10
SCHEMBL1733640 0.70 CYP3A4 (0.35) CYP3A4ALDH1A1TSHRHSD17B10MAPT
SCHEMBL2394153 0.69 MAPT (0.39) CYP3A4ALDH1A1TSHRHSD17B10MAPT
SCHEMBL11236482 0.69 CYP3A4 (0.37) CYP3A4EPHX2ALDH1A1TSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7501529-B2 7-Ethynyl-2,4,9-trithiaadamantane and related methods THE UNIVERSITY OF AKRON (US) 2009-03-10 US claimed
US-20080177094-A1 7-Ethynyl-2,4,9-Trithiaadamantane and Related Methods AKRON, THE UNIVERSITY OF 2008-07-24 US claimed
WO-2005003089-A2 7-ETHYNYL-2,4,9-TRITHIAADAMANTANE AND RELATED METHODS THE UNIVERSITY OF AKRON (US) 2005-01-13 WO claimed
US-8066914-B2 7-ethynyl-2,4,9-trithiaadamantane and related methods UNIVERSITY OF AKRON (US) 2011-11-29 US disclosed
US-8066914-B2 7-ethynyl-2,4,9-trithiaadamantane and related methods UNIVERSITY OF AKRON (US) 2011-11-29 US disclosed
US-20100072425-A1 7-ETHYNYL-2,4,9-TRITHIAADAMANTANE AND RELATED METHODS THE UNIVERSITY OF AKRON (US) 2010-03-25 US disclosed
US-20100072425-A1 7-ETHYNYL-2,4,9-TRITHIAADAMANTANE AND RELATED METHODS THE UNIVERSITY OF AKRON (US) 2010-03-25 US disclosed
US-7501529-B2 7-Ethynyl-2,4,9-trithiaadamantane and related methods THE UNIVERSITY OF AKRON (US) 2009-03-10 US disclosed
US-7501529-B2 7-Ethynyl-2,4,9-trithiaadamantane and related methods THE UNIVERSITY OF AKRON (US) 2009-03-10 US disclosed
US-20080177094-A1 7-Ethynyl-2,4,9-Trithiaadamantane and Related Methods AKRON, THE UNIVERSITY OF 2008-07-24 US disclosed
US-20080177094-A1 7-Ethynyl-2,4,9-Trithiaadamantane and Related Methods AKRON, THE UNIVERSITY OF 2008-07-24 US disclosed
WO-2005003089-A3 7-ETHYNYL-2,4,9-TRITHIAADAMANTANE AND RELATED METHODS UNIV AKRON (US) 2005-09-29 WO disclosed
WO-2005003089-A2 7-ETHYNYL-2,4,9-TRITHIAADAMANTANE AND RELATED METHODS THE UNIVERSITY OF AKRON (US) 2005-01-13 WO disclosed
WO-2005003089-A2 7-ETHYNYL-2,4,9-TRITHIAADAMANTANE AND RELATED METHODS THE UNIVERSITY OF AKRON (US) 2005-01-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080177094-A1 7-Ethynyl-2,4,9-Trithiaadamantane and Related Methods ALKBH2, TET1, AOX1 CYP3A4 835/4885EPHX2 176/4885ALDH1A1 8/4885
US-20100072425-A1 7-ETHYNYL-2,4,9-TRITHIAADAMANTANE AND RELATED METHODS ALKBH2, AOX1, TET1 CYP3A4 850/4885EPHX2 151/4885ALDH1A1 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.